
Annual report 2025
added 04-11-2026
China SXT Pharmaceuticals EPS Ratio 2011-2026 | SXTC
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio China SXT Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.32 | -28.6 | -178 | -138 | -3.82 | 33.3 | 0.075 | 0.059 | 0.059 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.3 | -178 | -35.2 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-0.09 | $ 5.12 | 11.55 % | $ 345 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.97 | 6.43 % | $ 9.55 B | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
2.39 | $ 320.13 | -3.98 % | $ 41.9 B | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | ||
|
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
-2.45 | $ 7.66 | 3.23 % | $ 75.7 M | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
-1.42 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-1.11 | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 21.81 | 0.6 % | $ 1.02 B | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 4.67 | -1.37 % | $ 766 M | ||
|
CymaBay Therapeutics
CBAY
|
-0.99 | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
42.2 | $ 102.12 | 2.66 % | $ 27.2 B | ||
|
Cabaletta Bio
CABA
|
-2.1 | $ 3.52 | 3.53 % | $ 354 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 3.08 | -4.94 % | $ 5.07 M | ||
|
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
-125 | - | -5.16 % | $ 5.39 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-0.02 | $ 1.35 | -12.9 % | $ 347 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
-0.78 | $ 4.26 | 0.47 % | $ 456 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 24.19 | -1.59 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
-1.08 | $ 1.61 | 8.05 % | $ 428 M | ||
|
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
-1.42 | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-2.4 | - | -16.75 % | $ 25.8 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
Clearside Biomedical
CLSD
|
-0.53 | - | - | $ 25.3 M | ||
|
Celldex Therapeutics
CLDX
|
-3.9 | $ 33.86 | -0.03 % | $ 2.25 B | ||
|
bluebird bio
BLUE
|
-1.93 | - | - | $ 546 M | ||
|
CNS Pharmaceuticals
CNSP
|
-35.8 | $ 2.75 | - | $ 1.22 M |